Frans Boch Waldorff

Frans Boch Waldorff

Auto-generated profile, based on publicly available information

Frans Boch Waldorff

Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2016 in Scandinavian Journal of Primary Health Care
Verified
Journal Article
Open access
PDF file
TWTora Grauers Willadsen
Tora Grauers Willadsen
ABAnna Bebe
Anna Bebe
RKRasmus Køster-Rasmussen
Rasmus Køster-Rasmussen
DJDorte Ejg Jarbøl
Dorte Ejg Jarbøl
AGAnn Dorrit Guassora
Ann Dorrit Guassora
NONiels de Fine Olivarius
Niels de Fine Olivarius
Objective is to explore how multimorbidity is defined in the scientific literature, with a focus on the roles of diseases, risk factors, and symptoms in the definitions. Design: Systematic review. Methods: MEDLINE (PubMed), Embase, and The Cochrane Library were searched for relevant publications up until October 2013. One author extracted the information. Ambiguities were resolved, and consensus reached with one co-author. Outcome measures were: cut-off point for the number of conditions included in the definitions of multimorbidity; setting; data sources; number, kind, duration, and severity of diagnoses, risk factors, and symptoms. We reviewed 163 articles. In 61 articles (37%), the cut-off point for multimorbidity was two or more conditions (diseases, risk factors, or symptoms). The most frequently used setting was the general population (68 articles, 42%), and primary care (41 articles, 25%). Sources of data were primarily self-reports (56 articles, 42%). Out of the 163 articles selected, 115 had individually constructed multimorbidity definitions, and in these articles diseases occurred in all definitions, with diabetes as the most frequent. Risk factors occurred in 98 (85%) and symptoms in 71 (62%) of the definitions. The severity of conditions was used in 26 (23%) of the definitions, but in different ways. The definition of multimorbidity is heterogeneous and risk factors are more often included than symptoms. The severity of conditions is seldom included. Since the number of people living with multimorbidity is increasing there is a need to develop a concept of multimorbidity that is more useful in daily clinical work. Key points The increasing number of multimorbidity patients challenges the healthcare system. The concept of multimorbidity needs further discussion in order to be implemented in daily clinical practice. Many definitions of multimorbidity exist and most often a cut-off point of two or more is applied to a range of 4–147 different conditions. Diseases are included in all definitions of multimorbidity. Risk factors are often included in existing definitions, whereas symptoms and the severity of the conditions are less frequently included.

1 June 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
WKWayne Katon
Wayne Katon
HPHenrik Sondergaard Pedersen
Henrik Sondergaard Pedersen
ARAnette Riisgaard Ribe
Anette Riisgaard Ribe
MFMorten Fenger-Grøn
Morten Fenger-Grøn
DDDimitry Davydow
Dimitry Davydow
MVMogens Vestergaard
Mogens Vestergaard
Diabetes mellitus (DM) and major depression are very common in Western populations. Type 2 DM occurs in approximately 8% to 14% of most Western populations,1 whereas approximately 25% of women and 16% of men will have a major depressive episode during their lifetime.2 Quiz Ref ID As many as 20% of persons with type 2 DM have comorbid depression.3 Furthermore, a recent meta-analysis has established a bidirectional link between depression and DM.4 Patients with comorbid depression and DM have poorer adherence to diet, smoking cessation, exercise, and medication regimens to control DM.5 Depression is also associated with increased cortisol levels,6 autonomic nervous system dysregulation,7 and increased inflammation,8 all of which worsen glycemic control. Therefore, patients with comorbid depression and DM have an increased risk for microvascular and macrovascular complications and mortality.9

17 July 2012 in BMJ
Verified
Journal Article
Open access
PDF file
FWF. B. Waldorff
F. B. Waldorff
DBD. V. Buss
D. V. Buss
AEA. Eckermann
A. Eckermann
MRM. L. H. Rasmussen
M. L. H. Rasmussen
NKN. Keiding
N. Keiding
GWG. Waldemar
G. Waldemar
Objective To assess the efficacy at 12 months of an early psychosocial counselling and support programme for outpatients with mild Alzheimer’s disease and their primary care givers. Design Multicentre, randomised, controlled, rater blinded trial. Setting Primary care and memory clinics in five Danish districts. Participants 330 outpatients with mild Alzheimer’s disease and their 330 primary care givers. Interventions Participating dyads (patient and primary care giver) were randomised to control support during follow-up or to control support plus DAISY intervention (multifaceted and semi-tailored counselling, education, and support). Main outcome measures Primary outcomes at 12 months for patients were change from baseline in mini mental state examination (MMSE) score, Cornell depression scale score, and proxy rated European quality of life visual analogue scale (EQ-VAS) score. For care givers, outcomes were change from baseline in geriatric depression scale (GDS 30 items) score and EQ-VAS score. Results Because of multiple testing, statistical significance was set at an adjusted P limit of <0.0005. At 12 months there were no significant differences between the two allocation groups in changes from baseline in the primary and secondary outcomes. However, although non-significant with the adjusted P limit, a small difference was observed for one of the primary patient outcomes (Cornell depression scale score) in patients in favour of the DAISY intervention group before and after adjusting for attrition (P=0.0146 and P=0.0103 respectively). Conclusions The multifaceted, semi-tailored intervention with counselling, education, and support for patients with mild Alzheimer’s disease and their care givers did not have any significant effect beyond that with well structured follow-up support at 12 months after adjustment for multiple comparisons. The small positive effect found in the unadjusted primary outcome addressing depressive symptoms in patients may call for further research focusing on patients with Alzheimer’s disease and comorbid depression. Trial registration ISRCTN74848736.

8 September 2021 in BMJ
Verified
Journal Article
Open access
PDF file
MCManuella Lech Cantuária
Manuella Lech Cantuária
FWFrans Boch Waldorff
Frans Boch Waldorff
LWLene Wermuth
Lene Wermuth
EPEllen Raben Pedersen
Ellen Raben Pedersen
APAslak Harbo Poulsen
Aslak Harbo Poulsen
MSMette Sørensen
Mette Sørensen
Objective: To investigate the association between long term residential exposure to road traffic and railway noise and risk of incident dementia. Design: Nationwide prospective register based cohort study. Setting: Denmark. Participants: 1 938 994 adults aged ≥60 years living in Denmark between 1 January 2004 and 31 December 2017. Main outcome measures: Incident cases of all cause dementia and dementia subtypes (Alzheimer’s disease, vascular dementia, and Parkinson’s disease related dementia), identified from national hospital and prescription registries. Results: The study population included 103 500 participants with incident dementia, and of those, 31 219 received a diagnosis of Alzheimer’s disease, 8664 of vascular dementia, and 2192 of Parkinson’s disease related dementia. Using Cox regression models, 10 year mean exposure to road traffic and railway noise at the most (L den max) and least (L den min) exposed façades of buildings were associated with a higher risk of all cause dementia. These associations showed a general pattern of higher hazard ratios with higher noise exposure, but with a levelling off or even small declines in risk at higher noise levels. In subtype analyses, both road traffic noise and railway noise were associated with a higher risk of Alzheimer’s disease, with hazard ratios of 1.16 (95% confidence interval 1.11 to 1.22) for road L den max ≥65 dB compared with <45 dB, 1.27 (1.22 to 1.34) for road L den min ≥55 dB compared with <40 dB, 1.16 (1.10 to 1.23) for railway L den max ≥60 dB compared with <40 dB, and 1.24 (1.17 to 1.30) for railway L den min ≥50 dB compared with <40 dB. Road traffic, but not railway, noise was associated with an increased risk of vascular dementia. Results indicated associations between road traffic L den min and Parkinson’s disease related dementia. Conclusions: This nationwide cohort study found transportation noise to be associated with a higher risk of all cause dementia and dementia subtypes, especially Alzheimer’s disease.

17 January 2012 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
FWFrans Boch Waldorff
Frans Boch Waldorff
VSVolkert Siersma
Volkert Siersma
AVAsmus Vogel
Asmus Vogel
GWGunhild Waldemar
Gunhild Waldemar

21 October 2021 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
SRSabrina Trappaud Rønne
Sabrina Trappaud Rønne
FRFrederik Rosenbæk
Frederik Rosenbæk
LPLine Bjørnskov Pedersen
Line Bjørnskov Pedersen
FWFrans Boch Waldorff
Frans Boch Waldorff
JNJesper Bo Nielsen
Jesper Bo Nielsen
Jens SøndergaardJens Søndergaard
Jens Søndergaard
Background: An increasing number of countries legalise the use of medical cannabis or allow it for a narrow range of medical conditions. Physicians, and often the patients’ general practitioner, play a major role in implementing this policy. Many of them, however, perceive a lack of evidence-based knowledge and are not confident with providing patients with medical cannabis. The objectives of this review are to synthesise findings about hospital physicians’ and GPs’ experiences, attitudes, and beliefs towards the use of medical cannabis with the purpose of identifying barriers and facilitators towards providing it to their patients. Methods: Peer-reviewed articles addressing hospital physicians’ and GPs’ experiences, attitudes, and beliefs towards the use of medical cannabis were searched systematically in PubMed, Scopus, EMBASE, and the Cochrane Library. Results: Twenty-one articles were included from five different countries in which the medical cannabis laws varied. The studied physicians experienced frequent inquiries about medical cannabis from their patients (49–95%), and between 10 and 95% of the physicians were willing to prescribe and/or provide it to the patients, depending on setting, specialty and experience among the physicians. This review found that physicians experienced in prescribing medical cannabis were more convinced of its benefits and less worried about adverse effects than non-experienced physicians. However, physicians specialized in addiction treatment and certain relevant indication areas seemed more sceptical compared to physicians in general. Nevertheless, physicians generally experienced a lack of knowledge of clinical effects including both beneficial and adverse effects. Conclusion: This review indicates that GPs and hospital physicians from various specialties frequently experience patient demands for medical cannabis and to some degree show openness to using it, although there was a wide gap between studies in terms of willingness to provide. Hospital physicians and GPs’ experienced in prescribing are more convinced of effects and less worried of adverse effects. However, most physicians experience a lack of knowledge of beneficial effects, adverse effects and of how to advise patients, which may comprise barriers towards prescribing. More research, including larger studies with cohort designs and qualitative studies, is needed to further examine facilitators and barriers to physicians’ prescribing practices.